BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241225T080000
DTEND;TZID=Europe/Brussels:20241227T200000
DTSTAMP:20260526T151852
CREATED:20241113T103614Z
LAST-MODIFIED:20241113T103616Z
UID:8467-1735113600-1735329600@www.europabio.org
SUMMARY:2nd ESAB Digital Congress
DESCRIPTION:After the successful first digital ESAB Congress last year\, the Scientific Committee has decided that a digital ESAB congress will take place again this year from November 25-27. \n\n\n\nDeadline for abstract submission: 31 October 2024 \n\n\n\nESAB Aims \n\n\n\n\nto take initiatives in areas of growing scientific and industrial interest and importance in the field of applied biocatalysis\n\n\n\n\n\nto identify key topics which may be rate-limiting in the development of scientific progress and technological prospects in applied biocatalysis and to take steps to stimulate these areas\n\n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/2nd-esab-digital-congress/
CATEGORIES:Biomanufacturing Platform,External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/11/Event-Banner-E-Congress-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241210T080000
DTEND;TZID=Europe/Brussels:20241211T200000
DTSTAMP:20260526T151852
CREATED:20240531T115038Z
LAST-MODIFIED:20240603T072409Z
UID:7883-1733817600-1733947200@www.europabio.org
SUMMARY:The European Bioplastics Conference 2024
DESCRIPTION:We are happy to announce that the EBC 24 will take place on 10/11 December 2024 at the Titanic Hotel Berlin\, Germany.    \n\n\n\nThe European Bioplastics Conference is Europe’s leading business and discussion forum within the global bioplastics sector. More and more brands and manufacturers are embracing the potential of biopolymers\, and policy makers are increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries. Now is the time to put bioplastics at the top of the agenda of a biobased circular economy in Europe and beyond. \n\n\n\nThe registration for the EBC 24 is now open and we are excited to welcome you on 10/11 December 2024 in Berlin or online. \n\n\n\nThe hybrid format of this year’s event will again allow you to join either in person at the Titanic Hotel Berlin or comfortably log-in from your home base. Both of which offer unique networking opportunities. \n\n\n\n \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/the-european-bioplastics-conference-2024/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/05/External-Events-Banners-600-×-200px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241122T140000
DTEND;TZID=Europe/Brussels:20241122T160000
DTSTAMP:20260526T151852
CREATED:20241125T083939Z
LAST-MODIFIED:20241125T083942Z
UID:8482-1732284000-1732291200@www.europabio.org
SUMMARY:What's Next for Biotech & Biosecurity: EU & US Post Election Landscape
DESCRIPTION:Join our Healthcare Public Affairs Director\, Vlad Olteanu on Friday 22nd November to listen to What’s next for Biotech and Biosecurity in the EU & US post elections.  \n\n\n\n\nMore information & Registerion Here
URL:https://www.europabio.org/event/whats-next-for-biotech-biosecurity-eu-us-post-election-landscape/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/11/External-Events-Banners-600-×-200px-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241119T080000
DTEND;TZID=Europe/Brussels:20241119T200000
DTSTAMP:20260526T151852
CREATED:20240619T110353Z
LAST-MODIFIED:20240619T110641Z
UID:7976-1732003200-1732046400@www.europabio.org
SUMMARY:AseBio Green Innovation Forum
DESCRIPTION:Organized by AseBio\, the Spanish Bioindustry Association\, and Sodena the financial agent of the Government of Navarra\, the 5th edition of the AseBio Green Innovation Forum will be held in the Baluarte convention centerof Pamplona on November 19\, 2024. The event will showcase the opportunities that biotechnology can offer as a key tool in the transition towards a more sustainable\, carbon neutral and greener economic model.  The Green Innovation Forum is also firmly committed to achieving the objectives set out in the 2030 Agenda and the European Green Deal. The AseBio Green Innovation Forum will have an agenda of round tables and business meetings in which to address the most relevant aspects of innovation in biotechnology and the green economy. We will also seek to find solutions to medium-long term challenges such as climate change\, industrial transformation\, sustainable food\, or the development of bio-products\, among others. RegistrationRegistration for the Green Innovation Forum 24 is now open. Take advantage of the early bird rates until July 31st. \n\n\n\nPresent your companyCompanies that are members of AseBio or domiciled in Navarra can submit a proposal to present their company before an audience of specialized investors and companies at no extra cost of your registration fee. Sinx-minute presentations will be delivered onsite on November 19th\, 2024. Not all applications will be accepted. A selection committee will review and accept or decline all applications. The deadline to apply: is September 20\, 2024 \n\n\n\nIf you wish to become a member of AseBio please visit our website. \n\n\n\nSponsorship opportunities \n\n\n\nDo you wish to become a sponsor of the Green Innovation Forum? \n\n\n\nGreeen Innovation Forum 2024 will provide you with a unique opportunity to meet face-to-face within Spanish and international  cutting edge companies and research institutions in the green biotech space. \n\n\n\nSponsoring the event will help to create interest in your company\, products and services and also: \n\n\n\n\nRaise your profile within the Spanish and European biotech industry.\n\n\n\n\n\nOther benefits\, as included in the different sponsorship packages.\n\n\n\n\n\n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/asebio-green-innovation-forum/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/06/External-Events-Banners-600-×-200px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241119T000000
DTEND;TZID=Europe/Brussels:20241119T235959
DTSTAMP:20260526T151852
CREATED:20241029T130646Z
LAST-MODIFIED:20241030T124012Z
UID:8442-1731974400-1732060799@www.europabio.org
SUMMARY:SME roundtable: Towards globally competitive European SMEs
DESCRIPTION:Europe is home to a vibrant community of Biotechnology SMEs contributing to the modernisation of the European industry. European biotechnology SMEs are the main drivers for innovation in healthcare\, food and feed\, industrial processes and manufacturing. \n\n\n\nThe Initiative on “Boosting Biotechnology and Biomanufacturing in the EU” published by the European Commission in March 2024 provides great prospects for EU SMEs. It highlights the EU ambition to deliver the benefits of biotechnology to support EU competitiveness and innovation alongside other global regions. One objective of the initiative is to identify ways to streamline EU legislation and its implementation to reduce Single Market fragmentation\, explore potential simplification of regulatory processes\, and shortening the time to market of biotechnological innovations. \n\n\n\nIn order to meet this objective\, EuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this roundtable to work as partners with all relevant stakeholders to guarantee the success of this Initiative. This roundtable session aims to provide a discussion forum for SME participants active in the sector to share their main driving forces and obstacles to accessing global markets and supply chains. The session will explore the essential elements required to speed up EU market access of biotech products.  \n\n\n\nThis event will be followed by a dedicated report exploring the sessions outcomes. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/sme-roundtable-towards-globally-competitive-european-smes/
CATEGORIES:EFIB,EuropaBio,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241112T090000
DTEND;TZID=Europe/Brussels:20241112T123000
DTSTAMP:20260526T151852
CREATED:20241029T085347Z
LAST-MODIFIED:20241029T085348Z
UID:8437-1731402000-1731414600@www.europabio.org
SUMMARY:Advancing bio-based innovations in the food industry: Focus on fermentation
DESCRIPTION:Join our Director General Dr Claire Skentelbery on the 12th of November in Brussels where she will be speaking at the DG GROW hosted hybrid workshop “Advancing bio-based innovations in the food industry: Focus on fermentation”. \n\n\n\nThe workshop will focus on the industrial applications of fermentation technologies by highlighting SMEs that are using biomass\, precision and gas fermentation. Their innovative technologies will be presented\, along with ways to promote scaling up production. These presentations will be followed by a Q&A session. \n\n\n\nAfter these industry insights\, a panel of experts will discuss topics such as research and innovation\, infrastructure\, the role of farmers\, public acceptance\, market development\, and profitability and pricing. In addition to the fermentation types presented at the beginning of the workshop\, micro fermentation will be discussed. \n\n\n\nDeadline for registrations: 4 November 2024 \n\n\n\n\nMore Information & Register Here
URL:https://www.europabio.org/event/advancing-bio-based-innovations-in-the-food-industry-focus-on-fermentation/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241104T080000
DTEND;TZID=Europe/Brussels:20241106T200000
DTSTAMP:20260526T151852
CREATED:20241009T073025Z
LAST-MODIFIED:20241009T074047Z
UID:8389-1730707200-1730923200@www.europabio.org
SUMMARY:BIO-Europe® 2024
DESCRIPTION:BIO-Europe® 2024 – 30th Annual International Partnering Conference  \n\n\n\nDates:November 4-6\, 2024 | Stockholm\, SwedenNovember 12–13\, 2024 | Digital PartneringVenue: Stockholmsmässan \n\n\n\nVenue address: Mässvägen 1\, 125 80 Stockholm Sweden \n\n\n\nJoin the 30th anniversary edition of BIO-Europe\, the biopharma partnering event that has grown with the industry\, innovated alongside it\, and remains the gathering place for meaningful and memorable conversations and connections. In 2023\, BIO-Europe reached new levels of attendance\, engagement\, and collaboration. 2024 promises to deliver quality opportunities for connection and partnering. The 30th annual BIO-Europe will take place November 4-6\, 2024 in Stockholm\, Sweden\, and it will convene over 5\,500 life science professionals representing more than 2\,800 companies from over 60 countries. Attendees will take part in 29\,000 one-to-one meetings over the course of the event. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/bio-europe-2024/
CATEGORIES:External
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241023T080000
DTEND;TZID=Europe/Brussels:20241024T200000
DTSTAMP:20260526T151852
CREATED:20241003T082016Z
LAST-MODIFIED:20241003T082123Z
UID:8368-1729670400-1729800000@www.europabio.org
SUMMARY:Regulating the Future of Food Conference
DESCRIPTION:Join our Industrial Biotechnology Senior Manager Lucie McMurtry on the 23rd and 24th of October in Amsterdam where she will be speaking at the Regulating the Future of Food Conference. \n\n\n\nGlobal innovation in food-tech is growing at an incredible pace and there are so many amazing new products and processes out there! This innovation is vital in making a difference to the planet by creating more sustainable and ‘greener’ food systems\, whilst also contributing to economic growth. \n\n\n\nRegulators are doing their best to keep up. They are all working on ways to evolve in line with innovation and create more effective and efficient ways to regulate novel foods\, whilst keeping safety as the key priority. However\, regulations are often seen as a barrier to innovation due to complex frameworks\, a lack of clear guidance and long evaluation timelines. \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/regulating-the-future-of-food-conference/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/Healthcare-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241022T080000
DTEND;TZID=Europe/Brussels:20241025T170000
DTSTAMP:20260526T151852
CREATED:20240611T071159Z
LAST-MODIFIED:20240611T071200Z
UID:7930-1729584000-1729875600@www.europabio.org
SUMMARY:World Orphan Drug Congress Europe 2024
DESCRIPTION:The World Orphan Drug Congress Europe is the largest and most established orphan drug & rare disease event worldwide. Meet over 2000 attendees\, hear from 250 leading speakers\, and connect with 130 exhibitors as we bring together experts from the start-to-finish of orphan drugs. From regulation and policy to global pricing and gene therapy\, the Congress has it covered. \n\n\n\nOur attendees include the most senior individuals across the industry\, including; R&D\, Gene Therapy and Rare diseases\, Precision/Personalised Medicine\, Genetic Disorders\, Patient Advocacy and Engagement\, Associations in ATMPs\, Investors\, Regulatory Affairs Professionals\, Governmental Bodies and many more … \n\n\n\nUse code “EUBIO20” to save an additional 20% off the Pharma/Biotech and Standard packages.
URL:https://www.europabio.org/event/world-orphan-drug-congress-europe-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/Event-Website-Banner-EBIO-WODC-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241008T100000
DTEND;TZID=Europe/Brussels:20241010T180000
DTSTAMP:20260526T151852
CREATED:20240828T135105Z
LAST-MODIFIED:20240828T135930Z
UID:8158-1728381600-1728583200@www.europabio.org
SUMMARY:CPHI Milan
DESCRIPTION:EuropaBio is pleased to partner with CPHI Milan 2024\, the biggest international pharmaceutical industry event for the thirty fifth anniversary edition. This year’s edition held from the 8th to the 10th of October in Fiera Milano\, Italy promises to a packed agenda with over 150 expert international speakers with over 100 content sessions. \n\n\n\nJoin our Director General Dr Claire Skentelbery this year where she will be speaking on the 9th of October to discuss how cultivated meat has the potential to revolutionise biologic manufacturing. Join her in Hall 3 – 3F97 at 16:15 on 09/10/2024 to find out more. \n\n\n\n \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/cphi-milan/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/CPHI-x-EuropaBio-2024-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241002T170000
DTEND;TZID=Europe/Brussels:20241002T193000
DTSTAMP:20260526T151852
CREATED:20240827T080153Z
LAST-MODIFIED:20240827T080535Z
UID:8151-1727888400-1727897400@www.europabio.org
SUMMARY:Enhancing Europe's Pharma and Biotech Competitiveness and Open Strategic Autonomy
DESCRIPTION:Join our Director General Dr Claire Skentelbery on 2 October 2024 where she will be speaking at the Novartis & BritCham event “Enhancing Europe’s Pharma and Biotech Competitiveness and Open Strategic Autonomy”. \n\n\n\n\nFind Out More & Register Here
URL:https://www.europabio.org/event/enhancing-europes-pharma-and-biotech-competitiveness-and-open-strategic-autonomy/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/08/BritCham-Novartis-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241001T170000
DTEND;TZID=Europe/Brussels:20241001T200000
DTSTAMP:20260526T151852
CREATED:20240517T115325Z
LAST-MODIFIED:20240517T115327Z
UID:7794-1727802000-1727812800@www.europabio.org
SUMMARY:Europe's Biotechnology & Biomanufacturing Future
DESCRIPTION:Biotechnology is a critical technology for global economic security\, health and sustainability. \n\n\n\nEurope’s world-leading research is translated into medicines\, food and next generation biomanufacturing across sectors in all European regions\, with employment\, skills and economic growth as part of a more sustainable\, healthy\, autonomous and competitive Europe. \n\n\n\nThe importance of biotechnology to Europe is now recognised through multiple actions. The European Commission Initiative “Boosting Biotechnology and Biomanufacturing in the EU” highlights the EU ambition to deliver biotechnology for competitiveness and societal impact alongside fast moving global regions\, whilst the Letta report highlights its significance within a well-functioning single market. It is amplified further through its specific inclusion in legislations such as STEP and the Net Zero Industry Act. \n\n\n\nEuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this reception to explore how biotechnology is used across sectors. Invited guests will meet the European innovators that deliver and use biotechnology and understand how it benefits the quality of life of all EU citizens. \n\n\n\nInnovative companies plus national and regional biotechnology associations will share their knowledge\, and guests will network across EU Institutions and other key stakeholders to discover how the European Union builds the future of biotechnology. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/europes-biotechnology-biomanufacturing-future/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Event-Banner-for-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240930T140000
DTEND;TZID=Europe/Brussels:20240930T160000
DTSTAMP:20260526T151852
CREATED:20240719T161756Z
LAST-MODIFIED:20240927T055832Z
UID:8081-1727704800-1727712000@www.europabio.org
SUMMARY:How does a Novel Food get to your plate?
DESCRIPTION:This EuropaBio’s webinar will focus on the pathway to market for Novel Foods\, from initial development in R&D through to consumer uptake while going through risk assessment and approval. Each speaker will cover a key point along the value chain\, including illustrative examples and case studies where relevant.    \n\n\n\nThe event will be moderated by Hannah Lester\, CEO at Atova Consulting.  \n\n\n\nThe confirmed speakers are: \n\n\n\n\nMuriel Dewilde\, Business Development Manager\, Bio Base Europe Pilot Plant\n\n\n\nErmolaos Ververis\, Scientific Officer Nutrition & Food Innovation Unit\, EFSA\n\n\n\nTimen Van Haaster\, Public Affairs & Communications Director\, HollandBio\n\n\n\nAnders Nelving\, Line Solution Manager\, Tetra Pak\n\n\n\nPer Falholt\, CSO at 21st Bio\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/how-does-a-novel-food-get-to-your-plate/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/07/banner-website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240924T140000
DTEND;TZID=Europe/Brussels:20240924T153000
DTSTAMP:20260526T151852
CREATED:20240604T072713Z
LAST-MODIFIED:20240919T083820Z
UID:7902-1727186400-1727191800@www.europabio.org
SUMMARY:The Future of Biotech: The Role of Legislation within Investment for Innovation
DESCRIPTION:To celebrate the start of European Biotech Week 2024\, EuropaBio is organising a webinar to discuss the critical intersection of legislation and investment into innovation within the biotech industry. With clear political support for European leadership in biotech\, ensuring EU legislation become key enabler of investment for innovation will be essential to the EU’s global competitiveness and strategic open autonomy. \n\n\n\nThis webinar will bring together representatives from the biotech industry\, investor community\, and European institutions to explore the essential elements required to foster a thriving biotech and life sciences ecosystem in the EU. \n\n\n\nThe confirmed speakers and full agenda are: \n\n\n\nWelcome and introduction  \n\n\n\nMarica Nobile (Assobiotec Federchimica) \n\n\n\nKeynote speech: EU biotech & biomanufacturing initiative  \n\n\n\nHans Ingels (DG GROW) \n\n\n\nPanel: Impact of EU Legislation on Investment Opportunities  \n\n\n\nYordan Aleksandrov (Pfizer) \n\n\n\nSME – Anna Handschuh (Future Affairs) \n\n\n\nNicoló Giacomuzzi-Moore (CBEJU) \n\n\n\nKatrien Swerts (Kurma Partners) \n\n\n\nMarica Nobile (Assobiotec Federchimica) will moderate the panel and deliver closing remarks. \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/the-future-of-biotech-the-role-of-legislation-on-investment-for-innovation/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/GENERAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240710T080000
DTEND;TZID=Europe/Brussels:20240711T170000
DTSTAMP:20260526T151852
CREATED:20240531T135225Z
LAST-MODIFIED:20240531T135227Z
UID:7893-1720598400-1720717200@www.europabio.org
SUMMARY:CURIOUS­ FUTURE INSIGHT™ CONFERENCE
DESCRIPTION:Over the millennia science & technology have steadily advanced\, but key unsolved challenges remain\, and much more is possible. The Curious – Future Insight™ Conference brings together some of the world’s brightest scientists and most accomplished innovators to present their work and explore the future of science and technology\, solving the challenges of today and enabling the dreams of a better tomorrow. \n\n\n\nThe Curious – Future Insight™ conference featurestop speakers and Nobel laureates from all over theworld\, among them: \n\n\n\n\nEmmanuelle Charpentier\, MPI (2018)\n\n\n\nSteven Chu\, Stanford University (2024)\n\n\n\nRobert Langer\, MIT (2024)\n\n\n\nSatya Nadella\, CEO Microsoft (2018)\n\n\n\nUğur Şahin\, CEO BioNTech (2024)\n\n\n\nRandy Schekman\, Berkeley (2024)\n\n\n\nThomas C. Südhof\, Stanford University (2024\, 2022)\n\n\n\nCraig Venter\, Craig Venter Institute (2018)
URL:https://www.europabio.org/event/curious-future-insight-conference/
CATEGORIES:Biomanufacturing Platform,External,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Curious-Insights-Banner-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240626T170000
DTEND;TZID=Europe/Brussels:20240626T190000
DTSTAMP:20260526T151852
CREATED:20240429T092024Z
LAST-MODIFIED:20240513T092250Z
UID:7743-1719421200-1719428400@www.europabio.org
SUMMARY:NAC Belgian Presidency Summer Reception
DESCRIPTION:EuropaBio\, bio.be/essenscia\, and flanders.bio biotechnology associations are organising a summer reception in Brussels for its members and invited guests to mark the end of the Belgium Council Presidency of the European Union and celebrate what best is made in Belgium – (beyond waffles and beers)\, biotechnology! \n\n\n\nWe will present the outcomes of our National Associations Council Presidency Summit “Made in Belgium for Europe“\, with recommendations on advanced therapies for rare diseases and microorganisms’ role in agricultural applications.  \n\n\n\nIf you wish for more details\, please reach out to communications@europabio.org
URL:https://www.europabio.org/event/nac-belgian-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-1-NAC-RECEPTION.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240613T113000
DTEND;TZID=Europe/Brussels:20240613T130000
DTSTAMP:20260526T151852
CREATED:20240513T142126Z
LAST-MODIFIED:20240513T142128Z
UID:7789-1718278200-1718283600@www.europabio.org
SUMMARY:Industrial Biotechnology Day (2nd edition) - Biotechnology as key enabling technology for EU Strategies and Ambitions
DESCRIPTION:Explore how industrial biotechnologies can achieve Europe’s environmental ambitions. Discussions will centre on exploring both regulatory frameworks and technological advancements\, identifying our core strengths and opportunities\, and pinpointing areas for improvement. From evaluating feedstocks and industrial capabilities to overcoming regulatory challenges\, join us in shaping a sustainable path forward for the European chemical industry through biotech innovations. \n\n\n\nThis session is organised by Cefic Sector Groups: EFCG\, EFG and Biochem Europe; EuropaBio and SICOS. \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotechnology-day-2nd-edition-biotechnology-as-key-enabling-technology-for-eu-strategies-and-ambitions/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Healthcare-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240516T090000
DTEND;TZID=Europe/Brussels:20240516T180000
DTSTAMP:20260526T151852
CREATED:20240118T152254Z
LAST-MODIFIED:20240118T152720Z
UID:7279-1715850000-1715882400@www.europabio.org
SUMMARY:Knowledge for Growth
DESCRIPTION:Get ready for the touchdown of Europe’s finest life sciences conference\, Knowledge for Growth\, on May 16\, 2024\, in the vibrant city of Antwerp\, Belgium!Elevate your network by rubbing shoulders with decision-makers from biotech\, pharma\, and MedTech\, alongside investors\, universities\, cutting-edge research institutes\, policymakers\, and competence providers. Join over 1000 life sciences trailblazers representing 500+ companies & organizations! Uncover the future with our riveting programme\, delivering key insights into the global and regional life sciences landscape. Engage in dynamic B2B partnering\, explore groundbreaking innovations at the trade fair\, and seize endless networking opportunities.Ready to be part of the life sciences revolution? Secure your spot now here! #KnowledgeForGrowth #KFG2024  \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/knowledge-for-growth-2/
LOCATION:Flanders Meeting & Convention Center Antwerp
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240514T200000
DTEND;TZID=Europe/Brussels:20240515T180000
DTSTAMP:20260526T151852
CREATED:20240311T142703Z
LAST-MODIFIED:20240311T142744Z
UID:7536-1715716800-1715796000@www.europabio.org
SUMMARY:AseBio Investor Day
DESCRIPTION:We are thrilled to announce that AseBio will hold the fifth edition of the AseBio Investor Day at the gorgeous Kursaal conference center in San Sebastián (Spain) on the 15th of May. The AseBio Investor Day is a forum that aims to connect the Spanish biotechnology industry with national and international investors. \n\n\n\nSince its first edition (Barcelona\, 2017)\, the event has attracted national and international investors\, contributing to give visibility to the national biotechnology industry. AseBio Investor Day also fosters networking between investors from Spain and the rest of the world. \n\n\n\nAseBio Investor Day includes a program of round tables where relevant topics on investment and finance will be addressed\, one-to-one meetings and startup pitch presentations. There will also be socials where you can meet your peers and biotech entrepreneurs. \n\n\n\nMeeting Spanish biotechnology is an opportunity to access new deal flow opportunities. Spain is the 9th largest originator of knowledge in biotechnology by number of papers. As of 2023 there were about 900 firms fully dedicated to biotechnology and 270 firms partially dedicated to biotechnology. In 2022 the sector attracted €142 million. \n\n\n\nIn our last edition more than 260 attendees participated in Investor Day and more than 330 one-to-one meetings were held through our matchmaking tool. \n\n\n\nSan Sebastián is a beautiful coastal town in the Spanish Basque Country. The city boasts stunning beaches\, a rich gastronomical tradition with one to the highest densities of Michelin star restaurants in the world\, splendid architecture and a thriving cultural life. The event will take place immediately after BioEquity\, which this year will be held on May 14 and May 15 in the same venue. \n\n\n\nIf you are planning to attend BioEquity why not extend your stay one more day and join us for an opportunity to meet Spanish biotechnology. Investors are cordially invited to participate in the AseBio Investor Day 2024. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/asebio-investor-day/
LOCATION:Kursaal Zurriola Hiribidea\, 1 20002 Donostia\, Guipuzkoa (Spain)
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Healthcare.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240507T140000
DTEND;TZID=Europe/Brussels:20240507T150000
DTSTAMP:20260526T151852
CREATED:20240429T082059Z
LAST-MODIFIED:20240429T084605Z
UID:7736-1715090400-1715094000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit - Report Launch
DESCRIPTION:“Policy pathways for biomanufacturing in Europe” was the theme of the Biomanufacturing Policy Summit 2024. The upcoming report will summarise the Summit’s keynote speeches and panel discussions and translate them into an analysis to Europe’s biomanufacturing strengths\, weaknesses\, opportunities and threats based on specific policies and industrial examples. \n\n\n\nThe report launch will also feature speakers who will respond to the report’s main conclusions and comment on their alignment with current challenges and future goals. \n\n\n\n\nHanna Freienstein\, Policy Officer\, DG GROW – European Commission\n\n\n\n⁠Jérôme Fabiano\, Deputy Director & Corporate Affairs Director\, EIT Health France\n\n\n\n⁠Per Falholt\, Chief Science Officer\, 21st.BIO\n\n\n\n\nThe boost to biotech and biomanufacturing needs a strong knowledge-based approach and the upcoming report aims to contribute to the discussion. Do not miss the opportunity and be up to date about biomanufacturing in Europe.
URL:https://www.europabio.org/event/europabios-biomanufacturing-policy-summit-report-launch/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-600-x-200-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260526T151852
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240319T143000
DTEND;TZID=Europe/Brussels:20240319T164500
DTSTAMP:20260526T151852
CREATED:20240213T092326Z
LAST-MODIFIED:20240213T093923Z
UID:7402-1710858600-1710866700@www.europabio.org
SUMMARY:Industrial biotech: Is Europe ready to harness its potential?
DESCRIPTION:A Science | Business closed-door roundtable\, organised in partnership with EuropaBio – followed by networking reception \n\n\n\nOnly By Invitation \n\n\n\n \n\n\nBackground Information \nIn recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes\, it has transformative potential for manufacturing\, waste use and the creation of sustainable products in sectors as varied as energy\, textiles\, plastics\, paper\, agriculture and water. While some core processes\, such as fermentation technology\, have been commercially deployed for around 50 years\, the speed of scientific progress and solution development are accelerating exponentially. As such\, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level.  \nThese take on greater importance when one considers other strategic priorities for the EU. First\, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP)\, it will need to leverage its full innovation capacity across sectors. Second\, as global demand grows for sustainable solutions to climate\, energy\, biodiversity and food system crises\, Europe is ideally positioned to take market leadership in various domains\, given its research excellence and strong industrial base. And third\, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience\, autonomy and competitiveness\, while biotechnology has also been recognised as a critical technology for Europe. \nYet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns\, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors\, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors?   \n As the EU prepares for its transition to a new Parliament and Commission\, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration: \nWhere can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP\, and what are the longer-term implications for boosting the global competitiveness of European companies?\nWhat should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors\, in line with other long-term strategies and objectives?\nWhich other steps are needed at EU and national level to build future capacity\, such as infrastructure and skills?\nIn which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels\, as has happened in the health sector?\nBeyond the CBE Joint Undertaking\, to what extent could Horizon Europe\, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?\nOn March 19\, Science|Business\, in cooperation with EuropaBio\, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door\, invitation-only roundtable. Drawing in part on latest research and real-world applications\, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing\, and to align its further development with the realisation of key EU policy goals.\n \n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFor more information\, please contact: denitsa.nikolova@sciencebusiness.ne \n\n\n\n \n\n\n\n \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotech-is-europe-ready-to-harness-its-potential/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240313T130000
DTEND;TZID=Europe/Brussels:20240313T200000
DTSTAMP:20260526T151852
CREATED:20231213T100000Z
LAST-MODIFIED:20240209T113124Z
UID:7082-1710334800-1710360000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org
URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20260526T151852
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240229T090000
DTEND;TZID=Europe/Brussels:20240301T170000
DTSTAMP:20260526T151852
CREATED:20240214T085311Z
LAST-MODIFIED:20240214T100345Z
UID:7415-1709197200-1709312400@www.europabio.org
SUMMARY:International Congress on Rare Diseases and Orphan Drugs 2024
DESCRIPTION:Navigating the Uncharted: Advancements\, Collaborations\, and Hope in Rare Diseases \n\n\n\nSupported by EuropaBio \n\n\n\n \n\n\n\nAbout the event: \n\n\n\nEmbrace the extraordinary journey into the world of rare diseases at our groundbreaking International Congress\, where innovation\, collaboration\, and hope converge! \n\n\n\nThe International Congress on Rare Diseases and Orphan Drugs is organized by Rare Diseases Greece (RDG)\, member of EURORDIS-Rare Diseases Europe and Boussias Events. \n\n\n\nFollowing the success of the previous years and having advanced the policy agenda on both a national and international level\, the Organizing Committee – consisting of Rare Diseases Greece (RDG)\, the 30-member umbrella organization that represents the country’s rare disease community\, brings together all the key initiatives and stakeholders currently shaping the rare disease landscape with the aim to set a course for the future of rare diseases. \n\n\n\nAttendance details: \n\n\n\nThursday\, 29.02.2024 (Hybrid | Technopolis City of Athens Gasholder 1 – Auditorium “Miltiadis Evert”) & Friday\, 01.03.2024 (Digital) \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nFind out more here
URL:https://www.europabio.org/event/international-congress-on-rare-diseases-and-orphan-drugs-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banner-International-Congress-on-Rare-Diseases-Orphan-Drugs-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240221T100000
DTEND;TZID=Europe/Brussels:20240221T120000
DTSTAMP:20260526T151852
CREATED:20231218T141335Z
LAST-MODIFIED:20240206T094606Z
UID:7206-1708509600-1708516800@www.europabio.org
SUMMARY:Made in Belgium for Europe\, National Associations' Council Presidency Summit
DESCRIPTION:Whether it’s microorganisms revolutionising manufacturing or advanced therapies for rare disease patients\, biotechnology is leading the way\, and Belgium is on it.  \n\n\n\nIf you are a researcher\, entrepreneur\, policy wonk\, or simply curious about the future of biotechnology\, join us in our free online conversation.  \n\n\n\nThis conversation will be public and held online on February 21\, 2024\, from 10:00 to 12:00. If you wish to attend our session\, please register. If you have any questions\, insights or suggestions\, do not hesitate to contact José Peres at j.peres@europabio.org. \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nDownload the Agenda
URL:https://www.europabio.org/event/made-in-belgium-for-europe-national-associations-council-presidency-summit/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Banner-Event-Website-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240214T080000
DTEND;TZID=Europe/Brussels:20240214T170000
DTSTAMP:20260526T151852
CREATED:20240130T125205Z
LAST-MODIFIED:20240130T125207Z
UID:7333-1707897600-1707930000@www.europabio.org
SUMMARY:Europe Rare Disease Summit 2024
DESCRIPTION:How to improve and learn about Government Plans\, Access & Financing\, Clinical Research and Innovation\, Artificial Intelligence and Data\, and Social & Patient. \n\n\n\nJoin our very own Healthcare Policy Senior Manager\, Adrien Samson in Madrid where he will be speaking in the panel “Innovation\, Funding and Access to Orphan Drugs: Challenges and Opportunities” between 12:15 and 13:00. \n\n\n\n \n\n\n\nWe are thrilled to announce the eagerly awaited second edition of the Europe Rare Disease Summit\, set to take place in February. Joining forces from all corners of Europe\, this prestigious event brings together leading researchers\, healthcare professionals\, patient advocates\, policymakers\, industry experts\, and rare disease patients and families. \n\n\n\nThe summit emphasizes the power of collaboration and solidarity in facing rare diseases. Together\, we can accelerate research\, enhance patient care\, and improve outcomes\, offering a brighter future for those affected by rare diseases. \n\n\n\nKey Objectives: \n\n\n\nEmpowering Patients: Putting patients at the heart of our efforts\, we strive to enhance their access to quality care and support\, while advocating for their rights and unique challenges. \n\n\n\nAdvancing Research: Renowned scientists will present groundbreaking discoveries\, fostering cross-disciplinary collaboration to propel rare disease research forward. \n\n\n\nBuilding Collaborative Networks: A platform for stakeholders to connect\, exchange ideas\, and form strategic partnerships\, bridging gaps in research\, treatment\, and support. \n\n\n\nInfluencing Policy: By engaging policymakers\, we seek to drive positive changes and better support the rare disease community. \n\n\n\nEngaging Program Highlights: Expect a dynamic lineup of keynote speeches\, interactive workshops\, panel discussions and networking opportunities. Share experiences\, learn from experts\, and inspire change. \n\n\n\nLocation and Dates: Prepare to be inspired in the vibrant setting of Madrid on February 14th. \n\n\n\nWho will Attend: \n\n\n\nRare Disease AdvocatesResearchers and ScientistsHealthcare ProfessionalsIndustry LeadersPolicymakers and Government RepresentativesPharmaceutical and Biotech CompaniesInvestors and Venture CapitalistsAcademics and Students
URL:https://www.europabio.org/event/europe-rare-disease-summit-2024/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/Event-Banner-ERDS-2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260526T151852
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240110T080000
DTEND;TZID=Europe/Brussels:20240125T170000
DTSTAMP:20260526T151852
CREATED:20231213T130812Z
LAST-MODIFIED:20231213T131255Z
UID:7175-1704873600-1706202000@www.europabio.org
SUMMARY:IHI Call Days - Calls 6 & 7
DESCRIPTION:The IHI Call Days are your one-stop-shop to get detailed information on our calls for proposals and network with potential partners for your consortium. \n\n\n\nIHI call 7 (single-stage) – info sessions\n\n\n\n10-12 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentWednesday 10 January | 10:30-11:30 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 10 January | 14:30-15:30 \n\n\n\nIHI rules and procedures for single-stage callsThursday 11 January | 10:30-11:30 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 11 January | 14:30-15:30 \n\n\n\nManaging the financial aspects of proposals for single-stage callsFriday 12 January | 10:30-11:30 \n\n\n\nIHI call 6 (two-stage) – info sessions\n\n\n\n15-16 January 2024 \n\n\n\nIHI rules and procedures for two-stage callsMonday 15 January | 14:30-15:30 \n\n\n\nCall 6\, topic 2: Development of practical guidance and recommendations for using real world data/real world evidence in healthcare decision-makingTuesday 16 January | 10:30-11:30 \n\n\n\nCall 6\, topic 1: Support healthcare system resilience through a focus on persistency in the treatment of chronic diseasesTuesday 16 January | 14:30-15:30 \n\n\n\nIHI call 7 (single-stage) – pitching sessions\n\n\n\n23-25 January 2024 \n\n\n\nCall 7\, topic 1: Improving clinical management of heart disease from early detection to treatmentTuesday 23 January | 14:30-16:00 \n\n\n\nCall 7\, topic 2: User-centric technologies and optimised hospital workflows for a sustainable healthcare workforceWednesday 24 January | 14:30-16:00 \n\n\n\nCall 7\, topic 3: Clinical validation of biomarkers for diagnosis\, monitoring disease progression and treatment responseThursday 25 January | 14:30-16:00
URL:https://www.europabio.org/event/ihi-call-days-calls-6-7/
CATEGORIES:Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/news-cover.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231201T083000
DTEND;TZID=Europe/Brussels:20231201T094500
DTSTAMP:20260526T151852
CREATED:20231031T084455Z
LAST-MODIFIED:20231031T084520Z
UID:7041-1701419400-1701423900@www.europabio.org
SUMMARY:EFIB 2023 Rotterdam Statement wider launch
DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png
END:VEVENT
END:VCALENDAR